N/A N=27 Effects of Exercise Training on Pelvic Floor Symptoms and Function in Adults With Constipation
Constipation
Primary: Severity of Constipation Symptoms — 0.96; 0.97; 0.63; 0.67 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
Constipation · Chronic Idiopathic Constipation · Irritable Bowel Syndrome With Constipation
Primary: Change From Baseline in Colonic Transit Time (CTT) — -727; -15; 366 minutes
N/A N=102 Maintenance Treatment for Children With Constipation
Constipation
Primary: Treatment Recovery — 33; 19 participants — p=0.024
Phase 2 N=154 Post-Operative Constipation Following Total Knee Arthroplasty
Constipation
Primary: Bowel Movement (BM) Within 3 Days of Surgery — 29; 32 Participants — p=0.41
Phase 4 N=826 An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
Irritable Bowel Syndrome With Constipation · Chronic Idiopathic Constipation
Primary: Number of Participants With Positive Treatment-Related Anti-Drug Antibodies (ADA) in Serum — 3; 1 Participants
N/A N=100 Effect of Electroacupuncture on Opioid-induced Constipation in Patients With Cancer
Opioid-induced Constipation in Patients With Cancer
Primary: Number of Participants With Response — 19; 4 participants
Phase 4 N=21 Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
Multiple Sclerosis · Constipation
Primary: Number of Spontaneous Bowel Movements in Patients With Multiple Sclerosis (MS)-Associated Constipation Per Day. — 3.4; 3.2 spontaneous bowel movements
N/A N=52 Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Irritable Bowel Syndrome · Constipation
Primary: Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline — 5.49; 6.52; -0.16; 0.2 hours
Phase 4 N=93 Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients
Chronic Diarrhea of Unknown Origin
Primary: Number of Participants With a 50 Percent Decrease in Mean Stool Count — 17 Participants
N/A N=349 Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: CSBM1 & CSBM2 Success Rate — 64; 33; 37; 17 Participants — p=0.0011
Phase 1 N=41 Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.
Chronic Constipation, Methanogenesis
Primary: Change in Methane Production — 10645; 14635 parts per million*minutes
Phase 3 N=1,725 An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
Irritable Bowel Syndrome With Constipation · Chronic Constipation
Primary: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — 65; 389; 454 Participants
Phase 3 N=1,554 An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
Chronic Constipation · Irritable Bowel Syndrome With Constipation
Primary: Number of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) — 399; 748 Participants
Phase 2 N=131 Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Opioid Induced Constipation
Primary: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements (SBMs) During Treatment — 1.96; 3.42; 1.44 Number of SBMs/week
Phase 2 N=81 Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Constipation
Primary: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements (SBMs) During Treatment — 1.40; 2.58 Number of SBMs/week